Pharmacologic Agents to Prevent and Treat Relapse After Allogeneic Hematopoietic Cell Transplantation

Overview

Journal Blood Adv

Specialty Hematology

Date 2018 Jan 4

PMID 29296897

Citations 9

Authors

Robert J Soiffer

Yi-Bin Chen

Affiliations

Soon will be listed here.

Citing Articles

Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.

Walia A, Tuia J, Prasad V Nat Rev Clin Oncol. 2023; 20(12):885-895.

PMID: 37828154 DOI: 10.1038/s41571-023-00823-5.

The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children.

Ilan U, Brivio E, Algeri M, Balduzzi A, Gonzalez-Vincent M, Locatelli F J Clin Med. 2023; 12(6).

PMID: 36983151 PMC: 10054172. DOI: 10.3390/jcm12062149.

Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Yang F, Feng Y, Dong C, Li Z, Wu T Blood Cell Ther. 2023; 4(3):54-57.

PMID: 36711057 PMC: 9847272. DOI: 10.31547/bct-2020-025.

Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal.

Bernasconi P, Borsani O Cancers (Basel). 2021; 13(13).

PMID: 34202000 PMC: 8268140. DOI: 10.3390/cancers13133170.

Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.

Amit O, Bar On Y, Perez G, Shargian-Alon L, Yeshurun M, Ram R Ann Hematol. 2021; 100(3):817-824.

PMID: 33442793 DOI: 10.1007/s00277-021-04398-y.

References

Blazar B, Carreno B, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H . Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003; 171(3):1272-7. DOI: 10.4049/jimmunol.171.3.1272. View

Davids M, Kim H, Bachireddy P, Costello C, Liguori R, Savell A . Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016; 375(2):143-53. PMC: 5149459. DOI: 10.1056/NEJMoa1601202. View

Ryan C, Sahaf B, Logan A, OBrien S, Byrd J, Hillmen P . Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016; 128(25):2899-2908. PMC: 5179333. DOI: 10.1182/blood-2016-06-715284. View

Goodyear O, Dennis M, Jilani N, Loke J, Siddique S, Ryan G . Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012; 119(14):3361-9. DOI: 10.1182/blood-2011-09-377044. View

Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D . Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017; 35(11):1154-1161. PMC: 5455603. DOI: 10.1200/JCO.2016.70.7091. View

Stein E, DiNardo C, Pollyea D, Fathi A, Roboz G, Altman J . Enasidenib in mutant relapsed or refractory acute myeloid leukemia. Blood. 2017; 130(6):722-731. PMC: 5572791. DOI: 10.1182/blood-2017-04-779405. View

Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring U . Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005; 106(2):458-63. DOI: 10.1182/blood-2004-05-1746. View

Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S . Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biol Blood Marrow Transplant. 2015; 22(2):385-390. PMC: 4728172. DOI: 10.1016/j.bbmt.2015.09.004. View

Lindsley R, Saber W, Mar B, Redd R, Wang T, Haagenson M . Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017; 376(6):536-547. PMC: 5438571. DOI: 10.1056/NEJMoa1611604. View

10.

Sammons S, Pratz K, Smith B, Karp J, Emadi A . Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol. 2014; 89(9):936-8. PMC: 4144402. DOI: 10.1002/ajh.23782. View

11.

Oshikawa G, Kakihana K, Saito M, Aoki J, Najima Y, Kobayashi T . Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2014; 169(5):756-9. DOI: 10.1111/bjh.13248. View

12.

Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton W, Metzner B . Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013; 31(13):1624-30. DOI: 10.1200/JCO.2012.47.1862. View

13.

Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T . Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults. Br J Haematol. 2017; 178(1):106-111. DOI: 10.1111/bjh.14652. View

14.

Ribera J, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J . Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2009; 95(1):87-95. PMC: 2805727. DOI: 10.3324/haematol.2009.011221. View

15.

Konopleva M, Pollyea D, Potluri J, Chyla B, Hogdal L, Busman T . Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016; 6(10):1106-1117. PMC: 5436271. DOI: 10.1158/2159-8290.CD-16-0313. View

16.

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A . Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2011; 26(3):381-9. PMC: 3306138. DOI: 10.1038/leu.2011.234. View

17.

DeFilipp Z, Chen Y . Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(12):2134-2140. DOI: 10.1016/j.bbmt.2016.08.021. View

18.

Blazar B, Taylor P, Panoskaltsis-Mortari A, Sharpe A, Vallera D . Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999; 162(11):6368-77. View

19.

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

20.

Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M . Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2012; 27(6):1254-62. DOI: 10.1038/leu.2012.352. View